Literature DB >> 17616708

Induction of postsurgical tumor immunity and T-cell memory by a poorly immunogenic tumor.

Peisheng Zhang1, Anik L Côté, Victor C de Vries, Edward J Usherwood, Mary Jo Turk.   

Abstract

The generation of protective CD8 T-cell memory against tumor-expressed self-antigens is an important but elusive goal of cancer immunotherapy. The possibility that a progressive, poorly immunogenic tumor can induce T-cell memory against self-antigens has not previously been studied. Herein, we report that growth of the poorly immunogenic B16 melanoma in the absence of regulatory T cells (T(reg)) generates CD8 T-cell responses that develop into functional memory after the tumor has been surgically excised. Tumor-primed memory T cells recognized melanocyte differentiation antigens TRP-2/DCT and gp100 and persisted for as long as 5 months following surgical tumor excision. Phenotypic analysis showed that these cells develop into both central and effector memory T-cell subsets, which produce IFN-gamma and interleukin-2 on reencounter with antigen. Most importantly, tumor-primed memory T cells mediated the rejection of intradermal and systemically disseminated challenge tumors given 30 to 60 days following surgery. Tumor-excised mice also developed autoimmune vitiligo, showing that T(reg) cells prevent tissue-specific autoimmunity in tumor-bearing hosts. This study establishes that T(reg) depletion in tumor-bearing hosts drives the natural development of protective T-cell memory. Generating such responses may aid in the clinical management of tumor recurrence and metastasis following surgery.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17616708      PMCID: PMC2564800          DOI: 10.1158/0008-5472.CAN-07-1264

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  50 in total

1.  Requirement for CD4 T cell help in generating functional CD8 T cell memory.

Authors:  Devon J Shedlock; Hao Shen
Journal:  Science       Date:  2003-04-11       Impact factor: 47.728

2.  CD8+ T cell contraction is controlled by early inflammation.

Authors:  Vladimir P Badovinac; Brandon B Porter; John T Harty
Journal:  Nat Immunol       Date:  2004-07-11       Impact factor: 25.606

3.  Gammaherpesvirus persistence alters key CD8 T-cell memory characteristics and enhances antiviral protection.

Authors:  Joshua J Obar; Shinichiro Fuse; Erica K Leung; Sarah C Bellfy; Edward J Usherwood
Journal:  J Virol       Date:  2006-09       Impact factor: 5.103

4.  Immunological consequences of tumor excision: from active immunity to immunological memory.

Authors:  I Bursuker; R J North
Journal:  Int J Cancer       Date:  1986-02-15       Impact factor: 7.396

Review 5.  CD8+ T-cell memory in tumor immunology and immunotherapy.

Authors:  Christopher A Klebanoff; Luca Gattinoni; Nicholas P Restifo
Journal:  Immunol Rev       Date:  2006-06       Impact factor: 12.988

6.  CD4+ T-cell help controls CD8+ T-cell memory via TRAIL-mediated activation-induced cell death.

Authors:  Edith M Janssen; Nathalie M Droin; Edward E Lemmens; Michael J Pinkoski; Steven J Bensinger; Benjamin D Ehst; Thomas S Griffith; Douglas R Green; Stephen P Schoenberger
Journal:  Nature       Date:  2005-03-03       Impact factor: 49.962

7.  Cutting Edge: Anti-CD25 monoclonal antibody injection results in the functional inactivation, not depletion, of CD4+CD25+ T regulatory cells.

Authors:  Adam P Kohm; Jeffrey S McMahon; Joseph R Podojil; Wendy Smith Begolka; Mathew DeGutes; Deborah J Kasprowicz; Steven F Ziegler; Stephen D Miller
Journal:  J Immunol       Date:  2006-03-15       Impact factor: 5.422

8.  Tumor cells convert immature myeloid dendritic cells into TGF-beta-secreting cells inducing CD4+CD25+ regulatory T cell proliferation.

Authors:  François Ghiringhelli; Pierre E Puig; Stephan Roux; Arnaud Parcellier; Elise Schmitt; Eric Solary; Guido Kroemer; François Martin; Bruno Chauffert; Laurence Zitvogel
Journal:  J Exp Med       Date:  2005-09-26       Impact factor: 14.307

9.  Regulatory CD4+CD25+ T cells restrict memory CD8+ T cell responses.

Authors:  Mischo Kursar; Kerstin Bonhagen; Joachim Fensterle; Anne Köhler; Robert Hurwitz; Thomas Kamradt; Stefan H E Kaufmann; Hans-Willi Mittrücker
Journal:  J Exp Med       Date:  2002-12-16       Impact factor: 14.307

10.  Route of immunization with peptide-pulsed dendritic cells controls the distribution of memory and effector T cells in lymphoid tissues and determines the pattern of regional tumor control.

Authors:  David W Mullins; Stacey L Sheasley; Rebecca M Ream; Timothy N J Bullock; Yang-Xin Fu; Victor H Engelhard
Journal:  J Exp Med       Date:  2003-10-06       Impact factor: 14.307

View more
  28 in total

1.  In vivo Treg suppression assays.

Authors:  Creg J Workman; Lauren W Collison; Maria Bettini; Meenu R Pillai; Jerold E Rehg; Dario A A Vignali
Journal:  Methods Mol Biol       Date:  2011

2.  Autoimmune vitiligo does not require the ongoing priming of naive CD8 T cells for disease progression or associated protection against melanoma.

Authors:  Katelyn T Byrne; Peisheng Zhang; Shannon M Steinberg; Mary Jo Turk
Journal:  J Immunol       Date:  2014-01-08       Impact factor: 5.422

3.  Resident memory T cells in the skin mediate durable immunity to melanoma.

Authors:  Brian T Malik; Katelyn T Byrne; Jennifer L Vella; Peisheng Zhang; Tamer B Shabaneh; Shannon M Steinberg; Aleksey K Molodtsov; Jacob S Bowers; Christina V Angeles; Chrystal M Paulos; Yina H Huang; Mary Jo Turk
Journal:  Sci Immunol       Date:  2017-04-14

4.  Immune inhibitory molecules LAG-3 and PD-1 synergistically regulate T-cell function to promote tumoral immune escape.

Authors:  Seng-Ryong Woo; Meghan E Turnis; Monica V Goldberg; Jaishree Bankoti; Mark Selby; Christopher J Nirschl; Matthew L Bettini; David M Gravano; Peter Vogel; Chih Long Liu; Stephanie Tangsombatvisit; Joseph F Grosso; George Netto; Matthew P Smeltzer; Alcides Chaux; Paul J Utz; Creg J Workman; Drew M Pardoll; Alan J Korman; Charles G Drake; Dario A A Vignali
Journal:  Cancer Res       Date:  2011-12-20       Impact factor: 12.701

5.  BRAF inhibition alleviates immune suppression in murine autochthonous melanoma.

Authors:  Shannon M Steinberg; Peisheng Zhang; Brian T Malik; Andrea Boni; Tamer B Shabaneh; Katelyn T Byrne; David W Mullins; Constance E Brinckerhoff; Marc S Ernstoff; Marcus W Bosenberg; Mary Jo Turk
Journal:  Cancer Immunol Res       Date:  2014-09-02       Impact factor: 11.151

6.  Stimulation of the glucocorticoid-induced TNF receptor family-related receptor on CD8 T cells induces protective and high-avidity T cell responses to tumor-specific antigens.

Authors:  Anik L Côté; Peisheng Zhang; Jeremy A O'Sullivan; Valerie L Jacobs; Carli R Clemis; Shimon Sakaguchi; José A Guevara-Patiño; Mary Jo Turk
Journal:  J Immunol       Date:  2010-11-24       Impact factor: 5.422

7.  Autoimmune melanocyte destruction is required for robust CD8+ memory T cell responses to mouse melanoma.

Authors:  Katelyn T Byrne; Anik L Côté; Peisheng Zhang; Shannon M Steinberg; Yanxia Guo; Rameeza Allie; Weijun Zhang; Marc S Ernstoff; Edward J Usherwood; Mary Jo Turk
Journal:  J Clin Invest       Date:  2011-04-11       Impact factor: 14.808

8.  IL-35-mediated induction of a potent regulatory T cell population.

Authors:  Lauren W Collison; Vandana Chaturvedi; Abigail L Henderson; Paul R Giacomin; Cliff Guy; Jaishree Bankoti; David Finkelstein; Karen Forbes; Creg J Workman; Scott A Brown; Jerold E Rehg; Michael L Jones; Hsiao-Tzu Ni; David Artis; Mary Jo Turk; Dario A A Vignali
Journal:  Nat Immunol       Date:  2010-10-17       Impact factor: 25.606

Review 9.  Tumor-specific T-cell memory: clearing the regulatory T-cell hurdle.

Authors:  Anik L Côté; Edward J Usherwood; Mary Jo Turk
Journal:  Cancer Res       Date:  2008-03-15       Impact factor: 12.701

10.  Metastasectomy in older adults with urothelial carcinoma: Population-based analysis of use and outcomes.

Authors:  Bishoy M Faltas; Renee L Gennarelli; Elena Elkin; Daniel P Nguyen; Jim Hu; Scott T Tagawa
Journal:  Urol Oncol       Date:  2017-10-05       Impact factor: 3.498

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.